Anti-human Thymoglobulin

Phase 1Small molecule

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Anti-human Thymoglobulin is one of 4 small molecule programs targeting Hematological Malignancy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematological MalignancyNot yet recruiting

Hematological MalignancyPhase 1

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Hematological Malignancy

#DrugCompanyPhaseTrials

Fludara

Sanofi

Preclinical

1 2

Cytoxan

BBaxter Healthcare Corporation

Preclinical

2 3

Anti-human Thymoglobulin

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 1

1 4

CTA101

TThe First Affiliated Hospital with Nanjing Medical University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Hematological Malignancy

NCT07117175

Clinical

Trials by Indication[1]

Conditioning1 trial

ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT02938741·130 enrolled

Hematological Malignancy1 trial

A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy

Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT07117175·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-human Thymoglobulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-human Thymoglobulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-human Thymoglobulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Anti-human Thymoglobulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Conditioning1 trial

Hematological Malignancy1 trial

References

Drug Info

Quick Facts

Related News